In people with group 1 pulmonary arterial hypertension, what are the benefits and risks of combination therapy with a phosphodiesterase type 5 inhibitor (PDE5i) and an endothelin receptor antagonist (ERA), compared with either agent alone?

Cochrane Clinical Answers 2026

View at publisher

Authors: Bipin Thapa

DOI: 10.1002/cca.4707

Cited by: 0

References: 1

Fields of Study & Subjects

Pulmonary Hypertension Research and Treatments Vascular Anomalies and Treatments Heart Failure Treatment and Management

References 1